ESH CLL 2022 | Time-limited vs continuous therapy in CLL treatment
In this video, Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, shares some insights into the use of time-limited therapy versus continuous therapy in chronic lymphocytic leukemia (CLL). Dr Mato first explains the various treatment options available to patients, including Bruton’s tyrosine kinase (BTK) inhibitor monotherapy and combination therapy, as well as venetoclax plus obinutuzumab. Dr Mato then discusses the treatment options available to patients in the relapsed/refractory setting, including venetoclax plus rituximab and BTK inhibitors. Dr Mato concludes by explaining that there is no comparative data supporting one treatment regimen over the other, and that patient decisions vary depending on several factors, such as adverse event profile and presence of comorbidities. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
Disclosures
Research support: TG Therapeutics, Pharmacyclics, Abbvie, Adaptive Biotechnologies, Johnson and Johnson, Acerta / AstraZeneca, DTRM BioPharma, Sunesis, BeiGene, Genentech, Genmab, Janssen, Loxo Oncology, Nurix. Advisory/Consultancy/DSMB: TG Therapeutics, Pharmacyclics, Adaptive Biotechnologies, Abbvie, Johnson and Johnson, Acerta / AstraZeneca, DTRM BioPharma, Sunesis, AstraZeneca, BeiGene, Genentech, Janssen, Loxo Oncology
